2.4.0.82407404 - Disclosure - Fair Value Measurements (Level 3 Contingent Purchase Price) (Details)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$I2013Q2http://www.sec.gov/CIK0001113481instant2013-06-30T00:00:000001-01-01T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$I2012Q4http://www.sec.gov/CIK0001113481instant2012-12-31T00:00:000001-01-01T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDtruefalse$D2013Q2QTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDtruefalse$D2012Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$D2013Q2YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$D2012Q2YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$D2013Q2QTD_us-gaap_BusinessAcquisitionAxis_mdco_InclineTherapeuticsIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseIncline Therapeutics, Inc. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldimdco_InclineTherapeuticsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$D2012Q2_us-gaap_BusinessAcquisitionAxis_mdco_InclineTherapeuticsIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseIncline Therapeutics, Inc. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldimdco_InclineTherapeuticsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$D2013Q2YTD_us-gaap_BusinessAcquisitionAxis_mdco_InclineTherapeuticsIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseIncline Therapeutics, Inc. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldimdco_InclineTherapeuticsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$D2012Q2YTD_us-gaap_BusinessAcquisitionAxis_mdco_InclineTherapeuticsIncMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMemberhttp://www.sec.gov/CIK0001113481duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseIncline Therapeutics, Inc. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldimdco_InclineTherapeuticsIncMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseFair Value, Measurements, Recurring [Member]us-gaap_FairValueByMeasurementFrequencyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueMeasurementsRecurringMemberus-gaap_FairValueByMeasurementFrequencyAxisexplicitMemberfalsefalseFair Value, Inputs, Level 3 [Member]us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel3Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false USDtruefalse$I2013Q2_us-gaap_StatementBusinessSegmentsAxis_mdco_TargantaMemberhttp://www.sec.gov/CIK0001113481instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseTarganta [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldimdco_TargantaMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12false USDtruefalse$I2012Q4_us-gaap_StatementBusinessSegmentsAxis_mdco_TargantaMemberhttp://www.sec.gov/CIK0001113481instant2012-12-31T00:00:000001-01-01T00:00:00falsefalseTarganta [Member]us-gaap_StatementBusinessSegmentsAxisxbrldihttp://xbrl.org/2006/xbrldimdco_TargantaMemberus-gaap_StatementBusinessSegmentsAxisexplicitMemberusdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 4mdco_FairValueMeasurmentContingentPurchasePriceRollForwardmdco_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value Measurment, Contingent Purchase Price [Roll Forward]2false 5mdco_ContingentPurchasePricemdco_falsecreditinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse100524000100524USD$falsetruefalse2truefalsefalse1897100018971USD$falsetruefalse3truefalsefalse105807000105807USD$falsetruefalse4truefalsefalse2099500020995USD$falsetruefalse5truefalsefalse1897100018971USD$falsetruefalse6truefalsefalse2043100020431USD$falsetruefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse54240005424USD$falsetruefalse12truefalsefalse1897100018971USD$falsetruefalsexbrli:monetaryItemTypemonetaryNoncurrent portion of the fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangements.No definition available.false2Balance at beginning of period3false 5us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1us-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse00falsefalsefalse8truefalsefalse00falsefalsefalse9truefalsefalse8720000087200falsefalsefalse10truefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of (increase) in the value of right to a contingent consideration asset.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479 false2Contingent purchase price value of Incline as of January 4, 20134false 5us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1us-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-5283000-5283falsefalsefalse4truefalsefalse573000573falsefalsefalse5truefalsefalse-5647000-5647falsefalsefalse6truefalsefalse11370001137falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of gain (loss) recognized in the income statement for financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false2Fair value adjustment to contingent purchase price included in net income5false 5mdco_ContingentPurchasePricemdco_falsecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse100524000100524USD$falsetruefalse2truefalsefalse1897100018971USD$falsetruefalse3truefalsefalse100524000100524USD$falsetruefalse4truefalsefalse2156800021568USD$falsetruefalse5truefalsefalse100524000100524USD$falsetruefalse6truefalsefalse2156800021568USD$falsetruefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse54240005424USD$falsetruefalse12truefalsefalse1897100018971USD$falsetruefalsexbrli:monetaryItemTypemonetaryNoncurrent portion of the fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangements.No definition available.false2Balance at end of periodfalseFair Value Measurements (Level 3 Contingent Purchase Price) (Details) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.themedicinescompany.com/role/FairValueMeasurementsLevel3ContingentPurchasePriceDetails125